Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapport TherapeuticsRAPP -4.05%14 Cash-to-Debt is 43.16 as of Jun. 2026, which is 24% below its 10-year median of 56.43. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 5 warning signs investors should review. Among 1,393 Biotechnology companies, Rapport Therapeutics ranks better than 69.92% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Rapport Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 43.16.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Rapport Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Rapport Therapeutics's Cash-to-Debt or its related term are showing as below:
RAPP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 21.96 Med: 56.43 Max: No Debt
Current: 43.16
During the past 4 years, Rapport Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 21.96. And the median was 56.43.
RAPP's Cash-to-Debt is ranked better than 69.92% of 1393
companies
in the Biotechnology industry
Industry Median: 6.72
vs RAPP: 43.16
Rapport Therapeutics (NAS:RAPP) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Rapport Therapeutics Cash-to-Debt Related Terms
Rapport Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Rapport Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a Cash-to-Debt of 43.16 as of Jun. 2026. This is 24% below median its historical median of 56.43. Over the past decade, Rapport Therapeutics' Cash-to-Debt has ranged from 21.96 to 10,000.00. According to the industry distribution chart, Rapport Therapeutics ranks #419 out of 1393 companies in the Biotechnology industry, placing it in the top 30.1%.
Is Rapport Therapeutics' Cash-to-Debt too high?
Rapport Therapeutics' current Cash-to-Debt of 43.16 is 24% below median its 10-year median of 56.43. Over the past 10 years, this metric has ranged from a low of 21.96 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Rapport Therapeutics' value of 43.16 is 542.3% above this industry median. Based on the distribution chart, Rapport Therapeutics ranks #419 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Cash-to-Debt compare to AUPH and PVLA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #419 out of 1393 companies for Cash-to-Debt. This puts Rapport Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.72. Rapport Therapeutics' value of 43.16 is 542.3% above this benchmark. Historically, Rapport Therapeutics' own Cash-to-Debt has ranged from 21.96 to 10,000.00 over the past decade. While the company's 10-year median is 56.43 vs. the industry median of 6.72, Rapport Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current Cash-to-Debt of 43.16 is 542.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current Cash-to-Debt is 43.16, which is 24% below median its own 10-year median of 56.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Cash-to-Debt of 43.16. The current Cash-to-Debt is 43.16, which is 24% below median its 10-year median of 56.43 and 542.3% above the Biotechnology industry median of 6.72. Rapport Therapeutics' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Cash-to-Debt is 43.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
